Annual CFF
$43.46 M
-$87.58 M-66.83%
December 31, 2023
Summary
- As of February 12, 2025, SYRS annual cash flow from financing activities is $43.46 million, with the most recent change of -$87.58 million (-66.83%) on December 31, 2023.
- During the last 3 years, SYRS annual CFF has fallen by -$99.49 million (-69.60%).
- SYRS annual CFF is now -69.60% below its all-time high of $142.95 million, reached on December 31, 2020.
Performance
SYRS Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$0.00
-$41.00 K-100.00%
September 30, 2024
Summary
- As of February 12, 2025, SYRS quarterly cash flow from financing activities is $0.00, with the most recent change of -$41.00 thousand (-100.00%) on September 30, 2024.
- Over the past year, SYRS quarterly CFF has increased by +$5000.00 (+100.00%).
- SYRS quarterly CFF is now -100.00% below its all-time high of $142.06 million, reached on September 30, 2022.
Performance
SYRS Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$43.16 M
+$5000.00+0.01%
September 30, 2024
Summary
- As of February 12, 2025, SYRS TTM cash flow from financing activities is $43.16 million, with the most recent change of +$5000.00 (+0.01%) on September 30, 2024.
- Over the past year, SYRS TTM CFF has increased by +$53.78 million (+506.33%).
- SYRS TTM CFF is now -76.24% below its all-time high of $181.67 million, reached on March 31, 2021.
Performance
SYRS TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
SYRS Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -66.8% | +100.0% | +506.3% |
| 3 y3 years | -69.6% | +100.0% | -67.1% |
| 5 y5 years | -37.1% | +100.0% | -67.1% |
SYRS Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -66.8% | at low | -100.0% | +100.0% | -69.6% | +506.3% |
| 5 y | 5-year | -69.6% | at low | -100.0% | +100.0% | -76.2% | +506.3% |
| alltime | all time | -69.6% | >+9999.0% | -100.0% | +100.0% | -76.2% | +506.3% |
Syros Pharmaceuticals Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $0.00(-100.0%) | $43.16 M(+0.0%) |
| Jun 2024 | - | $41.00 K(-115.5%) | $43.15 M(-0.2%) |
| Mar 2024 | - | -$265.00 K(-100.6%) | $43.25 M(-0.5%) |
| Dec 2023 | $43.46 M(-66.8%) | $43.38 M(<-9900.0%) | $43.46 M(-509.2%) |
| Sep 2023 | - | -$5000.00(-103.6%) | -$10.62 M(-108.1%) |
| Jun 2023 | - | $140.00 K(-364.2%) | $131.45 M(+0.3%) |
| Mar 2023 | - | -$53.00 K(-99.5%) | $131.09 M(+0.0%) |
| Dec 2022 | $131.04 M(+85.9%) | -$10.70 M(-107.5%) | $131.04 M(-7.6%) |
| Sep 2022 | - | $142.06 M(<-9900.0%) | $141.84 M(<-9900.0%) |
| Jun 2022 | - | -$223.00 K(+139.8%) | -$287.00 K(-3687.5%) |
| Mar 2022 | - | -$93.00 K(-196.9%) | $8000.00(-100.0%) |
| Dec 2021 | $70.51 M(-50.7%) | $96.00 K(-243.3%) | $70.51 M(-61.1%) |
| Sep 2021 | - | -$67.00 K(-193.1%) | $181.22 M(-0.2%) |
| Jun 2021 | - | $72.00 K(-99.9%) | $181.52 M(-0.1%) |
| Mar 2021 | - | $70.41 M(-36.5%) | $181.67 M(+27.1%) |
| Dec 2020 | $142.95 M(+116.6%) | $110.80 M(>+9900.0%) | $142.95 M(+330.1%) |
| Sep 2020 | - | $236.00 K(+7.3%) | $33.24 M(+0.8%) |
| Jun 2020 | - | $220.00 K(-99.3%) | $32.99 M(-66.3%) |
| Mar 2020 | - | $31.69 M(+2810.3%) | $97.80 M(+48.2%) |
| Dec 2019 | $65.99 M | $1.09 M(-9175.0%) | $65.99 M(+1.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2019 | - | -$12.00 K(-100.0%) | $65.04 M(-0.5%) |
| Jun 2019 | - | $65.03 M(<-9900.0%) | $65.38 M(+289.1%) |
| Mar 2019 | - | -$115.00 K(-183.9%) | $16.80 M(-75.7%) |
| Dec 2018 | $69.08 M(+103.6%) | $137.00 K(-58.1%) | $69.08 M(-0.8%) |
| Sep 2018 | - | $327.00 K(-98.0%) | $69.64 M(+0.5%) |
| Jun 2018 | - | $16.45 M(-68.5%) | $69.28 M(-19.4%) |
| Mar 2018 | - | $52.17 M(+7438.6%) | $85.98 M(+153.3%) |
| Dec 2017 | $33.94 M(-62.5%) | $692.00 K(-2332.3%) | $33.94 M(+2.0%) |
| Sep 2017 | - | -$31.00 K(-100.1%) | $33.27 M(-61.3%) |
| Jun 2017 | - | $33.15 M(>+9900.0%) | $86.03 M(+64.4%) |
| Mar 2017 | - | $128.00 K(+433.3%) | $52.32 M(-42.2%) |
| Dec 2016 | $90.56 M(<-9900.0%) | $24.00 K(-100.0%) | $90.56 M(+0.7%) |
| Sep 2016 | - | $52.73 M(-9449.3%) | $89.95 M(+141.8%) |
| Jun 2016 | - | -$564.00 K(-101.5%) | $37.20 M(-2.3%) |
| Mar 2016 | - | $38.37 M(-6692.3%) | $38.09 M(<-9900.0%) |
| Dec 2015 | -$278.00 K(-100.4%) | -$582.00 K(+3537.5%) | -$278.00 K(-191.4%) |
| Sep 2015 | - | -$16.00 K(-105.0%) | $304.00 K(-5.0%) |
| Jun 2015 | - | $320.00 K(>+9900.0%) | $320.00 K(>+9900.0%) |
| Mar 2015 | - | $0.00 | $0.00 |
| Dec 2014 | $68.76 M | - | - |
FAQ
- What is Syros Pharmaceuticals annual cash flow from financing activities?
- What is the all time high annual CFF for Syros Pharmaceuticals?
- What is Syros Pharmaceuticals annual CFF year-on-year change?
- What is Syros Pharmaceuticals quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Syros Pharmaceuticals?
- What is Syros Pharmaceuticals quarterly CFF year-on-year change?
- What is Syros Pharmaceuticals TTM cash flow from financing activities?
- What is the all time high TTM CFF for Syros Pharmaceuticals?
- What is Syros Pharmaceuticals TTM CFF year-on-year change?
What is Syros Pharmaceuticals annual cash flow from financing activities?
The current annual CFF of SYRS is $43.46 M
What is the all time high annual CFF for Syros Pharmaceuticals?
Syros Pharmaceuticals all-time high annual cash flow from financing activities is $142.95 M
What is Syros Pharmaceuticals annual CFF year-on-year change?
Over the past year, SYRS annual cash flow from financing activities has changed by -$87.58 M (-66.83%)
What is Syros Pharmaceuticals quarterly cash flow from financing activities?
The current quarterly CFF of SYRS is $0.00
What is the all time high quarterly CFF for Syros Pharmaceuticals?
Syros Pharmaceuticals all-time high quarterly cash flow from financing activities is $142.06 M
What is Syros Pharmaceuticals quarterly CFF year-on-year change?
Over the past year, SYRS quarterly cash flow from financing activities has changed by +$5000.00 (+100.00%)
What is Syros Pharmaceuticals TTM cash flow from financing activities?
The current TTM CFF of SYRS is $43.16 M
What is the all time high TTM CFF for Syros Pharmaceuticals?
Syros Pharmaceuticals all-time high TTM cash flow from financing activities is $181.67 M
What is Syros Pharmaceuticals TTM CFF year-on-year change?
Over the past year, SYRS TTM cash flow from financing activities has changed by +$53.78 M (+506.33%)